Author at Microdose

Phillips Lytle

Phillips Lytle has a deep and broad knowledge of the regulatory and legal issues related to approval, marketing and use of medications to treat mental health conditions, having served as national science counsel for a global pharmaceutical company for over twenty years.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Law & Politics

1 Jul 2023

FDA Draft Guidance on Clinical Trials for Psychedelics: A Closer Look

This is the FDA’s first guidance focusing on psychedelic drug development. Phillips Lytle law firm takes a closer look....

By Phillips Lytle

Industry, Science

22 Sep 2022

APA Issues Position Statement on Psychedelics

This past July, America’s oldest medical association, the American Psychiatric Association (APA), released an official position statement related to psychedelics entitled “Position Statement on the Use of Psychedelic and Empathogenic...

By Phillips Lytle

Law & Politics

19 Aug 2022

BIPOC Patients Underrepresented in Ketamine Trials

Black, Indigenous and People of Color (BIPOC) experience rates of mental health disorders equal to or greater than non-Hispanic Whites, yet lack access to therapies and are underrepresented in emerging...

By Phillips Lytle

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

Latest News

You Might Also Like

11 Aug 2026

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On...

By Madison Roberts

28 Jul 2026

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape...

By Madison Roberts

13 Jul 2026

The Psychedelic Sector Has Grown Up. Wall Street Just Hasn’t Fully Realized It Yet

The sector experienced an early wave of enthusiasm fueled by bold promises, lofty valuations, and the belief that psychedelic medicine would quickly transform mental healthcare. Reality, however, proved more complicated....

By Madison Roberts

28 May 2026

Medical Psilocybin Act

New York lawmakers are officially considering the “Medical Psilocybin Act,” legislation that would create legal access to psilocybin therapy for conditions like PTSD, treatment-resistant depression, substance use disorders, end-of-life distress,...

By Madison Roberts

5 May 2026

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

By Madison Roberts

21 Apr 2026

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity. For...

By Madison Roberts

Phillips Lytle has a deep and broad knowledge of the regulatory and legal issues related to approval, marketing and use of medications to treat mental health conditions, having served as national science counsel for a global pharmaceutical company for over twenty years.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Conscious Collective

The viewpoints shared are exclusively those of the contributor and do not necessarily represent the perspectives of Microdose's editorial team or its publishers.

Follow us on social

WordPress Ads